Sign Up to like & get
recommendations!
0
Published in 2021 at "Translational Oncology"
DOI: 10.1016/j.tranon.2021.101244
Abstract: Introduction FLT3-ITD mutations occur in approximately 25% of patients with acute myeloid leukemia (AML) and are associated with poor prognosis. Despite initial efficacy, short duration of response and high relapse rates limit clinical use of…
read more here.
Keywords:
apg 2575;
itd mutant;
hqp1351;
flt3 itd ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2017.1317745
Abstract: The last decade has witnessed rapid advances in our understanding of molecular leukemogenesis providing valuable insights from which to explore new therapeutic avenues. Characterization of the muta...
read more here.
Keywords:
isocitrate dehydrogenase;
therapeutic targeting;
mutant aml;
targeting isocitrate ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Blood"
DOI: 10.1182/blood.2019001533
Abstract: In this issue of Blood, Garg et al report on their investigation of the molecular interaction between mutations affecting DNMT3A and NPM1, and internal tandem duplications (ITDs) of FLT3 in acute myeloid leukemia (AML). They…
read more here.
Keywords:
aml clever;
triple mutant;
hlf;
aml ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Cancers"
DOI: 10.3390/cancers15010029
Abstract: Simple Summary Acute myeloid leukemia (AML) with mutations in the tumor suppressor gene TP53 is rapidly lethal for most patients. Here, we investigated the preclinical activity of TP-0903, a multikinase inhibitor that inhibits kinases with…
read more here.
Keywords:
tp53 mutant;
cell;
mutant aml;
aml ... See more keywords